A Double-Masked, Randomized, Controlled, Multiple-dose Study to Evaluate the Efficacy, Safety, and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene with Advanced Vision Loss (SIRIUS)